Zynerba is conducting clinical studies of Zygel™ in a number of patients with a number of neuropsychiatric conditions in the United States, Australia, New Zealand and Europe. Zygel is an experimental treatment. This means that it is not approved by government regulatory bodies, including the United States Food and Drug Administration (FDA) and other agencies and must be tested to see if it is an effective and safe treatment.
FXS RECONNECT Trial – now enrolling
RECONNECT (Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome): Enrollment Ongoing
For more information regarding enrollment in RECONNECT, please see:
22q INSPIRE Trial – complete; open label-extension ongoing
INSPIRE (Assessing the Impact of Zygel [Transdermal Cannabidiol Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome). For more details click here.
Plan to initiate a Phase 3 program after U.S. Food and Drug Administration discussions and RECONNECT (FXS) topline results.
Read more about Zynerba’s clinical pipeline here.